Showing results (1331-1340 of 1,431) with videos related to
Sort By:
Pageof 144
The Journal of Hospital Infection|September 13, 2005
Using an integrated infection control strategy during outbreak control to minimize nosocomial infection of severe acute respiratory syndrome among healthcare workersM-Y Yen, Y E Lin, I-J Su, et al.Oncogene|July 29, 2014
Gα12 gep oncogene deregulation of p53-responsive microRNAs promotes epithelial-mesenchymal transition of hepatocellular carcinomaY M Yang, W H Lee, C G Lee, et al.Journal of Medicinal Chemistry|February 21, 2012
Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritisAnthony D William, Angeline C-H Lee, Anders Poulsen, et al.Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|August 13, 2015
Genetics of Apparently Sporadic Pheochromocytoma and Paraganglioma in a Chinese PopulationC H Lee, C Y Y Cheung, W S Chow, et al.Kidney Cancer (Clifton, Va.)|October 19, 2018
Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell CarcinomaM I Carlo, B Manley, S Patil, et al.Yonsei Medical Journal|April 11, 2001
Lower gastrointestinal bleeding due to cytomegalovirus ileal ulcers in an immunocompetent manS W Choi, J P Chung, Y K Song, et al.Journal of Medicinal Chemistry|September 4, 2024
Rational Design, Synthesis, and Structure-Activity Relationship of a Novel Isoquinolinone-Based Series of HBV Capsid Assembly Modulators Leading to the Identification of Clinical Candidate AB-836Andrew G Cole, Steven G Kultgen, Nagraj Mani, et al.Journal of Medicinal Chemistry|December 14, 2011
Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancerAnthony D William, Angeline C-H Lee, Kee Chuan Goh, et al.Evaluation & the Health Professions|April 2, 2014
Physician Scientist Training in the United States: A Survey of the Current LiteratureR O Kosik, D T Tran, Angela Pei-Chen Fan, et al.ACS Infectious Diseases|September 22, 2024
Control of Hepatitis B Virus with Imdusiran, a Small Interfering RNA TherapeuticEmily P Thi, Xin Ye, Nicholas M Snead, et al.Pageof 144